Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference

• Confirmed Objective Response Rate of 48 Percent in Patients with NTRK+ TKI-Pretreated Advanced Solid Tumors
  
• Confirmed Objective Response Rate of 62 Percent in NTRK+ TKI-Pretreated Advanced Solid Tumor Patients with Solvent Front Mutations
  
• Breakthrough Therapy Designation Recently Granted in Patients with NTRK+ Advanced Solid Tumors Who Have Progressed Following Treatment with 1 or 2 Prior TKIs
  
• Confirmed Objective Response Rate of 41 Percent in Patients with NTRK+ TKI-Naive Advanced Solid Tumors

Excerpt from the Press Release:

SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the presentation of early clinical data from the NTRK-positive TKI-naïve and TKI-pretreated advanced solid tumor cohorts (EXP-5 and EXP-6) of the ongoing TRIDENT-1 Phase 1/2 study of its lead drug candidate repotrectinib.

These data are being presented today at a plenary session at the Virtual International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC) being held October 7-10.

Click the button below to read the entire Press Release:

Continue Reading The Press Release